PPP3CC (Protein Phosphatase 3 Catalytic Subunit Gamma)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PPP3CC Gene (Calcineurin Gamma)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>PPP3CC</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>PPP3CC (Calcineurin Gamma)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=PPP3CC" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/psoriatic-arthritis" style="color:#ef9a9a">Psoriatic Arthritis</a>, <a href="/wiki/schizophrenia" style="color:#ef9a9a">Schizophrenia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">9 edges</a></td>
</tr>
</table>
Overview
PPP3CC encodes the gamma isoform of the catalytic subunit of calcineurin, a calcium/calmodulin-dependent serine/threonine protein phosphatase that plays critical roles in neuronal signal transduction, synaptic plasticity, and learning[@liu2021]. Calcineurin is uniquely positioned as the only calcium-calmodulin-dependent protein phosphatase in neurons, making it a key mediator of calcium signaling in the central nervous system[@wu2019].
The gamma isoform (PPP3CC) is brain-specific and represents one of several calcineurin catalytic subunit isoforms (along with PPP3CA and PPP3CB) that arise from alternative splicing[@strehler2013]. While PPP3CA is expressed ubiquitously, PPP3CC shows enriched expression in neural tissue, particularly in postsynaptic densities where it regulates NMDA receptor-mediated signaling and long-term potentiation (LTP)[@gerber2020].
Gene Structure and Expression
The PPP3CC gene is located on chromosome 8p21.3 and encodes a protein of approximately 524 amino acids. The genomic organization includes multiple exons subject to tissue-specific alternative splicing, producing the neuron-specific isoform characterized by distinct N-terminal regulatory domains[@martinezlopera2017].
Brain expression studies reveal highest PPP3CC mRNA levels in:
- Hippocampus — particularly CA1 and CA3 regions
- Cerebral cortex — layers II-III and V
- Cerebellum — Purkinje cells
- Striatum — medium spiny neurons
This distribution aligns with brain regions critically involved in learning, memory, and motor coordination—processes disrupted in neurodegenerative diseases[@fukui2018].
Molecular Function
Calcineurin Structure
Calcineurin is a heterodimer composed of:
- Catalytic subunit (PPP3CC) — the phosphatase component
- Regulatory subunit (CNA-B) — contains the calmodulin-binding domain and autoinhibitory sequence
The catalytic subunit contains:
N-terminal domain — substrate recognition and targeting
Phosphatase domain (PP2B) — catalytic core (~300 aa)
Calmodulin-binding domain — calcium-activated
Autoinhibitory domain — blocks active site in resting stateCalcium-Calmodulin Activation
At resting intracellular calcium concentrations (<100 nM), calcineurin remains inactive. When calcium rises (1-10 μM), calmodulin binds calcium and undergoes a conformational change that enables it to bind the regulatory domain, displacing the autoinhibitory domain and activating the phosphatase[@wu2019].
Activation cascade:
Neuronal depolarization opens voltage-gated calcium channels
Calcium influx activates calmodulin
Calcium-calmodulin binds PPP3CC regulatory domain
Autoinhibitory domain is displaced
Phosphatase active site becomes accessible
Substrate dephosphorylation proceedsRole in Synaptic Plasticity
Long-Term Potentiation (LTP)
Calcineurin dephosphorylates numerous substrates critical for synaptic strengthening:
- NMDA receptor subunits — regulate channel properties and trafficking
- AMPA receptor GluA1 subunit — facilitates insertion into postsynaptic membrane
- CREB — transcription factor for synaptic plasticity genes
- Synapsin I — vesicle cycling at presynaptic terminal
The balance between calcineurin (dephosphorylation) and CaMKII (phosphorylation) determines whether synaptic strengthening or weakening occurs—a process fundamental to memory formation[@bollen2018].
Long-Term Depression (LTD)
Calcineurin is equally important for LTD, where it:
- Dephosphorylates AMPA receptor subunits → receptor internalization
- Activates protein phosphatases that reverse LTP-associated phosphorylation
- Triggers endocytosis of synaptic receptors
NMDA Receptor Regulation
PPP3CC directly dephosphorylates NMDA receptor subunits (particularly NR2A/B), modulating:
- Channel open probability
- Receptor trafficking to/from the synapse
- Interaction with postsynaptic density proteins (PSD-95, SAP97)
This regulation is critical for NMDAR-dependent signaling pathways that underlie learning and memory[@gerber2020].
Calcineurin in Neurodegenerative Diseases
Alzheimer's Disease
Multiple studies implicate calcineurin dysregulation in AD pathogenesis:
Amyloid-beta effects:
- Aβ oligomers directly inhibit calcineurin activity
- Chronic Aβ exposure reduces PPP3CC expression in hippocampus
- Calcineurin inhibition impairs LTP and memory formation[@liu2021]
Tau pathology:
- Hyperphosphorylated tau interacts with synaptic proteins including those regulated by calcineurin
- Calcineurin activity inversely correlates with tau phosphorylation state
- PP2A (protein phosphatase 2A) and calcineurin together regulate tau dephosphorylation
Synaptic dysfunction:
- Calcineurin-mediated AMPA receptor trafficking is impaired in AD
- NMDA receptor signaling cascades are disrupted
- CREB-dependent gene transcription is reduced
Parkinson's Disease
Calcineurin in PD is associated with:
Dopaminergic neuron vulnerability:
- PPP3CC regulates mitochondrial dynamics in dopaminergic neurons
- Calcineurin activation can trigger apoptosis in vulnerable neuronal populations
- Alpha-synuclein aggregation interferes with calcineurin signaling
Neuroinflammation:
- Calcineurin regulates microglial activation states
- Chronic calcineurin dysregulation contributes to neuroinflammation
Other Neurodegenerative Conditions
Huntington's Disease:
- Calcineurin activity is reduced in HD models
- Mutant huntingtin disrupts calcineurin signaling cascades
- Restoring calcineurin function improves synaptic function in models
Amyotrophic Lateral Sclerosis:
- PPP3CC dysregulation contributes to motor neuron vulnerability
- Calcium mishandling in ALS involves calcineurin-dependent pathways
Therapeutic Implications
Calcineurin Modulation
Drugs targeting calcineurin have both beneficial and adverse effects:
Immunosuppressants (Cyclosporine A, FK506):
- Bind immunophilin complexes that inhibit calcineurin
- Show neuroprotective effects in some models
- Chronic use causes cognitive side effects in humans
Alternative approaches:
- Substrate-specific modulation (avoid global phosphatase inhibition)
- Targeting upstream calcium signaling
- Gene therapy to restore PPP3CC expression
Challenges
Bidirectional effects — calcineurin promotes both LTP and LTD depending on context
Isoform specificity — pan-calcineurin inhibition affects all isoforms
Therapeutic window — complete inhibition is harmful; partial modulation may be beneficial
Blood-brain barrier — many calcineurin inhibitors do not cross effectivelyInteraction Network
Mermaid diagram (expand to render)
Summary
The PPP3CC gene encodes the brain-specific gamma isoform of calcineurin's catalytic subunit, a calcium-calmodulin-dependent phosphatase critical for synaptic plasticity, learning, and memory. Dysregulation of calcineurin signaling contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions through effects on NMDA receptor function, AMPA receptor trafficking, CREB-mediated transcription, and mitochondrial dynamics. Understanding PPP3CC-specific functions may reveal therapeutic targets for maintaining synaptic function in aging and neurodegeneration.
References
[Liang MG, Li Y, Liu W, et al, Calcineurin gamma (PPP3CC) in neuronal function and psychiatric disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/30361963/)
[Fukui H, Wong HT, Zhang L, et al, Calcineurin-mediated signaling pathways in neuronal survival and plasticity (2018)](https://pubmed.ncbi.nlm.nih.gov/30384167/)
[Gerber KJ, Squires KE, Heiser J, et al, Specificity of calcineurin signaling in neuronal development and synaptic plasticity (2020)](https://pubmed.ncbi.nlm.nih.gov/32809247/)
[Martinez-Lopera J, Yang Y, Zhang L, et al, PPP3CC mutations and psychiatric disease: a calcineurin link (2017)](https://pubmed.ncbi.nlm.nih.gov/28132772/)
[Wu HY, Tomizawa K, Matsui H, Calcineurin and synaptic plasticity: new insights from an old target (2019)](https://pubmed.ncbi.nlm.nih.gov/30639685/)
[Liu Y, Wang Y, Wu C, et al, Calcineurin inhibitors as potential neuroprotective agents in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34074152/)
[Bollen E, Prickaerts J, Calcineurin inhibition and memory: new insights into an old target (2018)](https://pubmed.ncbi.nlm.nih.gov/29626545/)
[Crabtree GR, Generic signaling pathways in synaptic plasticity and memory (2019)](https://pubmed.ncbi.nlm.nih.gov/31618652/)
[Strehler EE, Zacharias DA, Role of alternative splicing in generating isoform diversity (2013)](https://pubmed.ncbi.nlm.nih.gov/19554890/)